In this study, we largely focus on the EGFR/ERBB2/MET gene amplification in late stage NSCLC, EGFR, ERBB2, and MET amplification are the major resistant mechanism for EGFR T790M mutation patients, account for 39.5% in Chabon, J.J et al’s paper [18]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.